The recent, dramatic price increases of life-saving prescription drugs appear to have seemingly no relationship to research and development costs, but instead follow corporate takeovers - a move that looks like little more than price gouging.
It's unacceptable, especially because many of these price increases are coming at the expense of seniors who live on a fixed income and who rely on their medications.
We have to get to the bottom of this. That's why this week, I'm announcing a bipartisan Senate investigation into pharmaceutical drug pricing.
Together, with the Chairman of the Senate Aging Committee, Republican Senator Susan Collins, we have requested documents and information from four pharmaceutical companies: Valeant Pharmaceuticals, Turing Pharmaceuticals, Retrophin Inc, and Rodelis Therapeutics.
You can read the letters HERE.
But the investigation doesn't stop there - we'll be holding our first hearing in December and follow-up hearings in the coming months.
I'm proud to lead this investigation, because not only do our nation's seniors depend on it, but YOU deserve answers.
No comments:
Post a Comment